(Q38065391)

28 August 2017

1 reference

title

Broadly neutralizing antibodies against HIV-1: templates for a vaccine (English)

1 reference

28 August 2017

1 reference

1

1 reference

28 August 2017

2

Rogier W Sanders

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

435

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

46-56

1 reference

Development of the antibody response in acute HIV-1 infection

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Antibody-based protection against HIV infection by vectored immunoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Challenges in the development of an HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Gene therapy as a vaccine for HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structure of an unliganded simian immunodeficiency virus gp120 core

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

HIV vaccines: mosaic approach to virus diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Antigenic conservation and immunogenicity of the HIV coreceptor binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Identification of a major co-receptor for primary isolates of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Cross‐Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Immunogenicity of HIV-1 envelope glycoprotein oligomers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Fc receptor-mediated antiviral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Diversity considerations in HIV-1 vaccine selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

A review of vaccine research and development: the human immunodeficiency virus (HIV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Evolutionary and immunological implications of contemporary HIV-1 variation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Determinants of protection among HIV‐exposed seronegative persons: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Molecular architecture of native HIV-1 gp120 trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The role of antibodies in HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Induction of immunity to human immunodeficiency virus type-1 by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The immune response during acute HIV-1 infection: clues for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The challenge of HIV-1 subtype diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

7 January 2021

Toward an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Broad neutralization coverage of HIV by multiple highly potent antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Antibody neutralization and escape by HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Structural definition of a conserved neutralization epitope on HIV-1 gp120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.10.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2012.10.004

1 reference

28 August 2017

1 reference